Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) posted earnings of $0.35/Share in the previous quarter, as compared to earnings of $0.29/share estimated by analysts. The difference between the estimated and actual earnings was $0.06 per share.
Among analysts who offered their Analysis on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)—6 analysts issued Strong buy for the stock, 5 analysts have given a Buy rating, 14 think it’s a HOLD, 0 reported it as Underperform, while 0 analyst issued a Sell rating. (These Recommendations are reported by Yahoo Finance and are only for the Current Month)
A number of analysts offered their Estimated Earnings analysis for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for the current quarter. 17 analysts projected on average Earnings. The High end of the forecast is $1.11/share, while the Low end is $0.08/share.
Average Revenue Estimate for the current quarter is $503.96 Million, according to consensus forecast of 17 analysts. The High end of the Estimate is $690 Million, while the Low end of the Estimate is $448 Million. The company had Year Ago Sales of $711.45 Million.
Price Target plays a critical role when it comes to the Analysis of a Stock. 20 Analysts think that the Price Target for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) might hit $98.95, however, the High Price Target and Low price Target are $140 and $75, respectively.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) share price Jumped 0.8% to reach $87.42 during the last trading session. The Market Cap of the company stands at 21.68 Billion. The stock has 52-week high of $103.73 and 52-week low of $71.46. The stock’s current distance from 20-Day Simple Moving Average (SMA20) is 4.66% where SMA50 and SMA200 are 9.07% and 0.34% respectively. The stock hit its 52-Week High on Aug 9, 2016 and 52-Week Low on Dec 22, 2016.
The Average Volume of the company is 1.42 Million, while the Relative Volume of the company is 0.72. The company’s P/E is 0 and Forward P/E ratio is 28.75.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shows its Return on Assets (ROA) value of -4.3 percent, while the Return on Equity (ROE) value is -10.4 percent and Return on Investment (ROI) value stands at -0.3 percent. The company’s Relative strength index is 65.61.
The Procter & Gamble Company (NYSE:PG)
6 analysts rated the stock of The Procter & Gamble Company (NYSE:PG) as ‘STRONG BUY’, 5 rated as ‘BUY’ and 8 issued a ‘HOLD’ rating. The score shows the rating on a scale of 1 to 5, where 1=strong buy and 5=strong sell. The highest and lowest price target given by the brokerage firms to the equity are $106 and $76, respectively. The mean price target is $90.53 (according to consensus of 17 analysts).
The Procter & Gamble Company (NYSE:PG) jumped 8.31 percent over the past one year, while it rose 3.96 percent year to date (YTD). The stock soared 1.9 percent over the last 6 months. The company’s quarterly performance represents an optimistic momentum of 2.74 percent, with a surge of 2.8 percent in the stock price over the last one month.
The stock is now trading at a distance of 1.96% from SMA-20. The stock is currently trading 3.75 percent higher from its SMA-50. The Procter & Gamble Company (NYSE:PG) has a Return on Assets of 12 percent, Return on Equity of 26.9 percent, while Return on Investment of 11.6 percent.
The company is expected to report earnings of 1.1 per share for the current quarter, according to consensus agreement of 10 analysts. The high end of the earnings forecast is $1.13 per share and low end is $1.06 per share.
The Procter & Gamble Company (NYSE:PG) is expected to report revenue of $16.66 Billion for the current quarter, according to consensus estimate of 9 analysts. The high end of the revenue guidance is $17.1 Billion and the low end is $16.28 Billion.
The Procter & Gamble Company’s growth estimate for the current quarter is 9.3, and 1.3 percent for the next quarter. Expected growth of The Procter & Gamble Company (NYSE:PG) for the next year 5 years is 7.5 percent (per annum), as compared to -0.94 percent (per annum) in the past 5 years.